IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY:
All dates and times listed above are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.tarsusrx.com for the latest information.
A live webcast of the presentation will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying three investigational medicines in clinical trials, including TP-03 for the treatment of Meibomian Gland Disease, which is currently being studied in a Phase 2a clinical trial, TP-04 for the potential treatment of Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of activity.
| Media Contact: |
| Adrienne Kemp |
| Sr. Director, Corporate Communications |
| (949) 922-0801 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Investor Contact: |
| David Nakasone |
| Head of Investor Relations |
| (949) 620-3223 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$72.93 |
| Daily Change: | -2.04 -2.72 |
| Daily Volume: | 544,585 |
| Market Cap: | US$3.080B |
August 06, 2025 February 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
